Agents and Actions

, Volume 20, Issue 1–2, pp 69–76 | Cite as

Inhibition of arachidonic acid-induced ear oedema as a model for assessing topical anti-inflammatory compounds

  • A. Crummey
  • G. P. Harper
  • E. A. Boyle
  • F. R. Mangan
Immunosuppression and Inflammation

Abstract

We have found that mouse ear oedema induced by the topical application of arachidonic acid is not a specific screen for compounds inhibiting the lipoxygenase or cyclo-oxygenase pathways of arachidonic acid metabolism. Although such compounds are able to reduce the oedema substantially, pharmacological agents such as histamine antagonists, phosphodiesterase inhibitors, free radical scavengers, and also various compounds not normally considered to have anti-inflammatory properties, can equally effectively reduce the oedema. A mutual potentiation of the effects of prostaglandins, leukotrienes and mast cell-derived histamine would allow many, but not all, of the active agents to be rationalised. The ability of compounds not influencing these three types of inflammatory mediators to reduce the oedematous response means the model is of limited value for directed screening.

Abbreviations used

5-HETE

5-hydroxyeicosatetraenoic acid

LTB4

leukotriene B4

NDGA

norkihydroguaiaretic acid

NSAIDs

non-steroidal anti-inflammatory drugs

NBT

nitroblue tetrazolium chloride

PG

prostaglandin (E1, A2, etc.)

THF

tetrahydrofuran

TxB2

thromboxane B2

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    S. Hammarström, M. Hamberg, B. Samuelsson, E. A. Duell, M. Stawiski and J. J. Voorhees,Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E 2 and prostaglandin F in epidermis of psoriasis. Proc. Natl. Acad. Sci. USA72, 5130–5134 (1975).PubMedGoogle Scholar
  2. [2]
    S. D. Brain, R. Camp, P. Dowd, A. Kobza Black and M. Greaves,The release of leukotriene B 4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J. Invest. Dermatol.83, 70–73 (1984).PubMedGoogle Scholar
  3. [3]
    R. D. R. Camp,Prostaglandins, hydroxy fatty acids, leukotrienes and inflammation of the skin. Clin. expl. Dermatol.7, 435–444 (1982).Google Scholar
  4. [4]
    R. Camp, R. Russell Jones, S. Brain, P. Wollard and M. Greaves,Production of intraepidermal microabscesses by topical application of leukoitriene B 4. J. Invest. Dermatol.82, 202–204 (1984).PubMedGoogle Scholar
  5. [5]
    E. Wong, R. D. Camp and M. W. Greaves,The responses of normal and psoriatic skin to single and multiple topical applications of leukotriene B 4. J. Invest. Dermatol.84, 421–423 (1985).PubMedGoogle Scholar
  6. [6]
    P. Crunkhorn and A. L. Willis,Cutaneous reactions to intradermal prostaglandins. Br. J. Pharmac.41, 49–56 (1971).Google Scholar
  7. [7]
    T. J. Williams and M. J. Peck,Role of prostaglandinmediated vasodilatation in inflammation. Nature270, 530–532 (1977).PubMedGoogle Scholar
  8. [8]
    N. A. Soter, R. A. Lewis, E. J. Corey and K. F. Austen,Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4)in human skin. J. Invest. Dermatol.80, 115–119 (1983).PubMedGoogle Scholar
  9. [9]
    G. A. Higgs, J. A. Salmon and J. A. Spayne,The inflammatory effects of hydroperoxy and hydroxy acid products of arachidonate lipoxygenase in rabbit skin. Br. J. Pharmac.74, 429–433 (1981).Google Scholar
  10. [10]
    R. J. Flower, E. A. Harvey and W. P. Kingston,Inflammatory effects of prostaglandin D 2 in rat and human skin. Br. J. Pharmac.56, 229–233 (1976).Google Scholar
  11. [11]
    M. A. Bray, F. M. Cunningham, A. W. Ford-Hutchison and M. J. H. Smith,Leukotriene B 4:a mediator of vascular permeability. Br. J. Pharmac.72, 483–486 (1981).Google Scholar
  12. [12]
    A. Ueno, K. Tanaka, M. Katori, M. Hayashi and Y. Arai,Species difference in increased vascular permeability by synthetic leukotriene C4 and D4. Prostaglandins21, 637–648 (1981).PubMedGoogle Scholar
  13. [13]
    J. M. Young, D. A. Spires, C. J. Bedord, B. Wagner, S. J. Ballaron and L. M. De Young,The mouse ear inflammatory response to topical arachidonic acid. J. Invest. Dermatol.82 367–371 (1984).PubMedGoogle Scholar
  14. [14]
    E. E. Opas, R. J. Bonney and J. L. Humes,Prostaglandin and leukotriene synthesis in mouse ears inflamed by arachidonic acid. J. Invest. Dermatol.84, 253–256 (1985).PubMedGoogle Scholar
  15. [15]
    P. Sonnino-Goldman, D. Donigi Ruzza, S. Hyman, E. S. Neiss, T. P. Pruss and P. S. Wolf,Comparative effects of topically applied REV 5901, phenidone and indomethacin on arachidonic acid-induced ear inflammation in DBA/2J mice. Agents and Actions16, 598–599 (1985).Google Scholar
  16. [16]
    R. P. Carlson, L. O'Neill-Davis, J. Chang and A. J. Lewis,Modulation of mouse ear edema by cyclo-oxygenase and lipoxygenase inhibitors. Agents and Actions16, 599 (1985).Google Scholar
  17. [17]
    E. C. Arner, B. L. Rule, M. S. Rudnick and W. Galbraith,Arachidonic acid-induced ear edema: correlation of swelling with production of lipoxygenase products. Agents and Actions16, 600–601 (1985).Google Scholar
  18. [18]
    J. Berkenkopf, C. Casmer and A. Watnick,Drug activities in arachidonic acid and croton oil induced inflammations. Agents and Actions16, 601–602 (1985).Google Scholar
  19. [19]
    R. P. Carlson, L. O'Neill-Davis, J. Chang and A.J. Lewis,Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Agents and Actions17, 197–204 (1985).PubMedGoogle Scholar
  20. [20]
    W. Bors, M. Saran, E. Lengfelder, C. Michel, C. Fuchs and C. Frenzel,Detection of oxygen radicals in biological reactions. Photochemistry and Photobiology28, 629–638 (1978).PubMedGoogle Scholar
  21. [21]
    D. Lagunoff and E.Y. Chi,Cell biology of mast cells and basophils. InThe cell biology of inflammation (Handbook of Inflammation 2) pp. 216–265 (Ed. G. Weissmann). Elsevier/North-Holland Biomedical Press. Amsterdam 1980.Google Scholar
  22. [22]
    J. B. Malick, J. B. Patel, A. I. Salama, B. A. Meiners, R. E. Giles and M. E. Goldberg,Tracazolate: a novel nonsedative anxiolytic. Drug Development Res.4, 61–73 (1984).Google Scholar
  23. [23]
    C. D. Nicholson and R. Wilke,The apparent tissue selectivity of some alkylxanthines as phosphodiesterase inhibitors. Naun. Schmied. Arch. Pharmacol.332 (Suppl. R33 (1986).Google Scholar
  24. [24]
    J. F. Riley and G. B. West,Histamine liberation in the rat and mouse. Arch. int. Pharmacodyn. CII 304–313 (1955).Google Scholar
  25. [25]
    R. J. Flower, J. N. Wood and L. Parente,Macrocortin and the mechanism of action of the glucocorticoids. Adv. Infl. Res.7, 61–70 (1984).Google Scholar
  26. [26]
    S. J. Foster and M. E. McCormick,The mechanism of the anti-inflammatory activity of glucocorticosteroids. Agents and Actions16, 58–59 (1985).PubMedGoogle Scholar
  27. [27]
    K. Sugio, K. Ohuchi, M. Sugata and S. Tsurufuji,Suppression by dexamethasone of vascular permeability responses induced with leukotrienes C and D in the rat skin. Prostaglandins21, 649–653 (1981).PubMedGoogle Scholar
  28. [28]
    K. B. Glaser and R. S. Jacobs,Molecular pharmacology of manoalide: inactivation of bee venom phospholipase A 2. Biochem. Pharmacol.35, 449–453 (1986).PubMedGoogle Scholar
  29. [29]
    W. E. M. Lands,Mechanisms of action of anti-inflammatory drugs. Adv. Drug Res.14, 147–164 (1985).Google Scholar
  30. [30]
    F. A. Kuehl, J. L. Humes, R. W. Egan, E. A. Ham, G. C. Beveridge and C. G. Van Arman,Role of prostaglandin endoperoxide PGG 2 in inflammatory processes. Nature265, 170–173 (1977).PubMedGoogle Scholar
  31. [31]
    P. Needleman, A. Raz, M. S. Minkes, J. A. Ferrendelli and H. Sprecher,Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc. Natl. Acad. Sci. USA76, 944–948 (1979).PubMedGoogle Scholar
  32. [32]
    T. H. Lee, J.-M. Mencia-Huerta, C. Shih, E. J. Corey, R. A. Lewis and K. F. Austen,Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B 5 and the double lipoxygenase product. J. Biol. Chem.259, 2383–2389 (1984).PubMedGoogle Scholar
  33. [33]
    W. C. Pickett, C. Dondero and R. McReynolds,Replacement of arachidonic acid with eicosapentaenoic acid attenuates the fatty acid or phorbol myristate acetate induced mouse ear edema. Agents and Actions16, 602 (1985).Google Scholar
  34. [34]
    R. P. Schleimer, D. W. MacGlashan, E. S. Schulman, S. P. Peters, G. K. Adams, N. F. Adkinson and L. M. Lichtenstein,Human mast cells and basophils-Structure, function, pharmacology and biochemistry. Clin. Rev. Allergy1, 327–341 (1983).PubMedGoogle Scholar
  35. [35]
    J. Chang, L. O'Neill-Davis, B. Lamb, R. P. Carlson and A. J. Lewis,The utility of arachidonic acid-treated mouse ear inflammatory model as a potential screen for lipoxygenase inhibitors. Agents and Actions16, 600 (1985).Google Scholar

Copyright information

© Birkhäuser Verlag 1987

Authors and Affiliations

  • A. Crummey
    • 1
  • G. P. Harper
    • 1
  • E. A. Boyle
    • 1
  • F. R. Mangan
    • 1
  1. 1.Beecham Pharmaceuticals Research DivisionMedicinal Research CentreHarlowUK

Personalised recommendations